Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Anti-tumor necrosis factor (TNF)-α agents like infliximab have transformed ulcerative colitis (UC) treatment.
• However, primary and secondary treatment failure affects up to 50% of UC patients, highlighting an unmet medical need.
• Novel biologic therapies are crucial for managing moderate-to-severe UC.

Purpose of the Study:

• To review randomized controlled trials (RCTs) of biological agents for moderate-to-severe UC in adults.
• To aid clinical decision-making in selecting appropriate biologic therapies.
• To compare the efficacy of different biologic agents when head-to-head trials are unavailable.

Main Methods:

• Review of randomized controlled trials (RCTs) for biologic agents in moderate-to-severe UC.
• Network meta-analysis to estimate relative efficacy between different biological interventions.
• Consideration of clinical factors beyond efficacy, including patient convenience, administration route, cost, and safety profiles.

Main Results:

• New biologic agents, including anti-TNF-α antibodies (adalimumab, golimumab) and vedolizumab (α4β7 integrin blocker), expand UC treatment options.
• The availability of multiple biologics complicates treatment selection, necessitating guidance for optimal drug choice and sequencing.
• Network meta-analysis provides comparative efficacy data in the absence of direct head-to-head trials.

Conclusions:

• The expanded range of biologics improves the likelihood of successful UC treatment.
• Clinical decisions should integrate efficacy, safety, patient preferences, and cost-effectiveness.
• Further research, including head-to-head trials, is needed to definitively guide biologic selection in UC management.